CSTL News

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Castle Biosciences Reports Third Quarter 2025 Results

Castle Biosciences to Participate in Upcoming Investor Conferences

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025